公司资料
Genmab 股价、新闻与催化剂
- 股票代码:
- GMAB
- 交易所:
- NASDAQ
- 行业:
- Antibody Drugs
- 所在地:
- Copenhagen, Denmark
股票表现
32.84 USD (+2.82%)
收盘价
最后更新: 2026年8月17日
14.6B USD
市值
股价为何变动
As of Aug 17, 2026, GMAB closed up 2.82% at $32.84. No new same-company headline was identified in the current news window.
公司概览
业务概览
Genmab is an antibody-focused biotechnology company with a long record of discovering and advancing differentiated cancer therapeutics. The company is known for its antibody engine, its partnered programs, and its ability to turn discovery into commercial or royalty-based value.
所在地与行业分类
Headquartered in Copenhagen, Denmark and listed on Nasdaq Copenhagen and as an ADR in the U.S., Genmab is a global biotechnology company. Its footprint spans Europe and the United States.
商业模式特征
Genmab combines internal R&D with partnered programs, milestone revenue, and royalty income from successful antibodies. Investors follow clinical data, partner progress, and whether the company can keep producing validated antibodies from its discovery platform.
生物医药行业定位
Genmab sits in the premium end of antibody biotech because it has both scientific credibility and economic leverage from partnerships. The stock can move on data, deal flow, or royalty updates, making it a platform-driven catalyst name.
未来催化剂
- Genmab’s next three months are likely to focus on epcoritamab, combination data, and any label or expansion steps that deepen the antibody franchise. That readout matters because it decides whether the asset is ready for a larger and more expensive development step. If the data come in cleanly, the market tends to give the broader platform behind the program more credit.
近期新闻
相似股票
商业成熟度、治疗领域或催化剂模式相近的同行公司。